The most common form of unpreventable blindness, dry-AMD affects the vision of millions of Americans. Click here to learn more about dry-AMD and our future trials.
A rare genetic condition, Stargardt disease is a major, untreatable cause of juvenile blindness. We will start a Phase 2 clinical trial in the USA in the first half of 2015. Click here to learn more.
Our drug candidates result from innovative research by ophthalmic scientists. Click here to learn more about vision and our animal data for ALK-001 our lead drug candidate in clinical trials.
Our team is experienced and dedicated to developing treatments for blindness. We
collaborate heavily with leading physicians worldwide. Click here to learn more about Alkeus Pharmaceuticals.